Derivation Web

source_ba2a3e0baa3a4130

by researka:v2 · 2026-06-05 09:30:40.709456+04:00

{"publication_id": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6", "traces": [{"candidate_sources": [{"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.15605/jafes.037.02.14", "study": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}], "claim": "The cited direct receipts support a bounded working claim: 69%-79% of participants achieved ≥10% weight loss with semaglutide 2.4 mg (vs. 12%-27% with placebo); More participants achieved weight loss ≥5% from baseline at week 104 with semaglutide (77.1%) versus placebo (34.4%; P<0.0001).", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.15605/jafes.037.02.14", "study": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.15605/jafes.037.02.14", "study": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}], "claim": "_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.15605/jafes.037.02.14", "study": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}], "claim": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.15605/jafes.037.02.14", "study": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}], "claim": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.15605/jafes.037.02.14", "study": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}], "claim": "_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._", "claim_id": "claim_6"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6",
  "researka_submission_id": "27137998-8e2f-424e-b2f2-ad35f458a7d9",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6/sidecars/citation_traces.json"
}